Fractionated radiosurgery for 9L gliosarcoma in the rat brain

Kim, Jae Ho; Khil, Mark S.; Kolozsvary, Andrew; Gutiérrez, Jorge; Brown, Stephen L.

doi:10.1016/s0360-3016(99)00273-4

Cited by 28 publications

(25 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This particularly radioresistant tumor requires high radiation dose deposition for palliation or even ablation; a 40-Gy radiosurgical dose controlled only 50% of 9LGS (19). Tumor responses to MRT on D 55 T 45 in our study were markedly heterogeneous.…”

Section: Discussionmentioning

confidence: 68%

Preferential Effect of Synchrotron Microbeam Radiation Therapy on Intracerebral 9L Gliosarcoma Vascular Networks

Bouchet

Lemasson

Duc

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

155

185

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 68%

Preferential Effect of Synchrotron Microbeam Radiation Therapy on Intracerebral 9L Gliosarcoma Vascular Networks

Bouchet

Lemasson

Duc

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

155

185

View full text Add to dashboard Cite

show abstract

“…A 5-min waiting period was observed before slow withdrawal of the needle. The hole in the skull was sealed with bone wax, and the incision was closed (Kim et al, 1999(Kim et al, , 2003. The tumor was allowed to grow for 2 days before the rats received twice-daily i.p.…”

Section: Methodsmentioning

confidence: 99%

9L Gliosarcoma Cell Proliferation and Tumor Growth in Rats Are Suppressed by N-Hydroxy-N′-(4-butyl-2-methylphenol) Formamidine (HET0016), a Selective Inhibitor of CYP4A

Guo

Roman

Fenstermacher

et al. 2005

J Pharmacol Exp Ther

View full text Add to dashboard Cite

The present study examined the effects of N-hydroxy-NЈ-(4-butyl-2 methylphenyl) formamidine (HET0016), a selective inhibitor of the formation of 20-hydroxyeicosatrienoic acid (20-HETE) on the growth of 9L rat gliosarcoma cells in vitro and in vivo. After 48 h of incubation, HET0016 reduced the proliferation of 9L in vitro by 55%, and this was associated with a fall in p42/p44 mitogen-activated protein kinase and stress-activated protein kinase/c-Jun NH 2 -terminal kinase phosphorylation and increased apoptosis. HET0016 inhibited epidermal growth factor (EGF) and platelet-derived growth factor (PDGF)-induced proliferation and diminished phosphorylation of PDGF receptors. A stable 20-HETE analog increased 9L cell proliferation. In vivo, chronic administration of HET0016 (10 mg/kg/day i.p.) for 2 weeks reduced the volume of 9L tumors by 80%. This was accompanied by a 4-fold reduction in the mitotic index, a 3-to 4-fold increase in the apoptotic index, and a ϳ50% decrease in vascularization in the tumor. HET0016 treatment increased mean survival time of the animals from 17 to 22 days. Liquid chromatography/mass spectrometry experiments indicated that neither 9L cells grown in vitro nor 9L tumors removed produce 20-HETE when incubated with arachidonic acid. The normal surrounding brain tissue, however, avidly makes 20-HETE, and this activity is selectively inhibited by HET0016. These results suggest that HET0016 may be the prototype of a class of antigrowth compounds that may be efficacious for treating malignant brain tumors. In vivo, it may act in part by inhibiting the formation of 20-HETE by the surrounding tissue. However, the antiproliferative effects of HET0016 on 9L cells in vitro seem unrelated to its ability to inhibit the formation of 20-HETE.

show abstract

“…A 1.0 mm burr-hole was made in the skull 2.5 mm anterior to bregma and 2.0 mm lateral to the midline on the right. Ten thousand 9L tumor cells in a volume of 5 l were implanted at a depth of 3 mm into the brain parenchyma using a 10 l Hamilton syringe (Hamilton Co., Reno, NV, USA) with a 26-gauge needle (Kim et al, 1999). The burr-hole was sealed with sterile bone wax, the skin was closed with sterile silk suture.…”

Section: Implantation Of Tumor Cellsmentioning

confidence: 99%

Application of arsenazo III in the preparation and characterization of an albumin-linked, gadolinium-based macromolecular magnetic resonance contrast agent

Nagaraja¹,

Croxen²,

Panda³

et al. 2006

Journal of Neuroscience Methods

View full text Add to dashboard Cite

Fractionated radiosurgery for 9L gliosarcoma in the rat brain

Cited by 28 publications

References 21 publications

Preferential Effect of Synchrotron Microbeam Radiation Therapy on Intracerebral 9L Gliosarcoma Vascular Networks

Preferential Effect of Synchrotron Microbeam Radiation Therapy on Intracerebral 9L Gliosarcoma Vascular Networks

9L Gliosarcoma Cell Proliferation and Tumor Growth in Rats Are Suppressed by N-Hydroxy-N′-(4-butyl-2-methylphenol) Formamidine (HET0016), a Selective Inhibitor of CYP4A

Application of arsenazo III in the preparation and characterization of an albumin-linked, gadolinium-based macromolecular magnetic resonance contrast agent

Contact Info

Product

Resources

About